Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Global Market Report 2024

The attention deficit hyperactivity disorder (ADHD) therapeutics market size has grown strongly in recent years. It will grow from $12.37 billion in 2023 to $13.21 billion in 2024 at a compound annual growth rate (CAGR) of 6.8%. The growth observed during the historical period can be credited to increased diagnostic awareness and screening initiatives, a rising prevalence of ADHD, advancements in treatment methods, expansion of healthcare infrastructure, and the broadening of health insurance coverage.

The attention deficit hyperactivity disorder (ADHD) therapeutics market size is expected to see strong growth in the next few years. It will grow to $16.42 billion in 2028 at a compound annual growth rate (CAGR) of 5.6%. The projected growth during the forecast period is driven by advancements in genetic research and personalized medicine, rising awareness of mental health issues, and the implementation of global and national mental health programs. Additionally, the expansion of telehealth services and the incorporation of behavioral therapies are contributing factors. Key trends anticipated in the forecast period include technological breakthroughs in treatment methods, ongoing research and development efforts, the integration of digital therapeutics, the adoption of precision medicine strategies, and advancements in drug delivery systems.

The upward trend in attention-deficit hyperactivity disorder (ADHD) diagnoses is anticipated to drive the expansion of the ADHD therapeutics market in the foreseeable future. This surge in ADHD cases reflects a growing populace grappling with this neurodevelopmental condition. Therapies for ADHD address its multifaceted manifestations, striving to enhance symptom control, functional limitations, quality of life, and overall wellness among those affected. Notably, as of January 2023, reports from the Guardian, a US-based news outlet, indicate that around 170,000 identified patients were prescribed ADHD treatments in 2022, marking a 20.4% surge from the 141,000 patients noted during the corresponding period in 2021. Hence, the escalating prevalence of ADHD is a key driver of growth in the ADHD therapeutics market.

Prominent players in the ADHD therapeutics sector are concentrating on advancing digital solutions such as Endeavor over-the-counter (OTC) digital therapeutics for ADHD to cater to the escalating demand for digital innovations and the increasing need for remote healthcare services. Digital therapeutics entail evidence-based therapeutic interventions driven by sophisticated software programs to prevent, manage, or treat medical conditions. These interventions are intended for standalone use or in conjunction with conventional medical treatments. For instance, in June 2023, Akili, a US-based digital health firm, unveiled an over-the-counter (OTC) iteration of its video game-based digital therapy tailored for adults with ADHD. Branded as EndeavorOTC, this solution aims to enhance attention, time management, and organizational skills. Moreover, this initiative follows the success of Akili's FDA-approved prescription video game therapy, EndeavorRx, for pediatric ADHD patients. The OTC variant offers adults a non-pharmacological option for managing ADHD symptoms.

In March 2022, Optum Inc., a healthcare services provider based in the United States, completed the acquisition of Refresh Mental Health for $700 million. This strategic move aims to strengthen Optum's presence as a provider of outpatient mental and behavioral health services. The acquisition will enable Optum to broaden its offerings of effective behavioral care to patients and foster closer integration between medical and behavioral health services. Refresh Mental Health, a US-based company, specializes in providing a range of mental and behavioral health services, such as ADHD psychiatry and therapy.

Major companies operating in the attention deficit hyperactivity disorder (ADHD) therapeutics market report are Pfizer Inc., Johnson And Johnson Services Inc., Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical's, Eli Lilly and Company, Otsuka Pharmaceutical Co. Ltd., UCB S.A., Amneal Pharmaceuticals LLC, Lupin Ltd., Mallinckrodt Pharmaceuticals Inc., Hisamitsu Pharmaceutical Co. Inc., Purdue Pharma L.P., Arbor Pharmaceuticals LLC, Tris Pharma Inc., NEOS Therapeutic Inc., Concert Pharmaceuticals Inc., Vayarin AG, Rhodes Pharmaceuticals L.P., KemPharm Inc., Impax Laboratories Inc., Aevi Genomic Medicine, Adlon Therapeutics L.P., Ironshore Pharmaceuticals Inc., Highland Therapeutics Inc.

North America was the largest region in the attention deficit hyperactivity disorder (ADHD) therapeutic market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the attention deficit hyperactivity disorder (ADHD) therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the attention deficit hyperactivity disorder (ADHD) therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Attention deficit hyperactivity disorder (ADHD) therapeutics encompasses a spectrum of treatments and interventions designed to manage symptoms and enhance the functioning of individuals diagnosed with ADHD. ADHD is a neurodevelopmental disorder characterized by symptoms such as inattention, hyperactivity, and impulsivity, which significantly disrupt daily activities and development. The primary goal of ADHD therapeutics is to improve attention, impulse control, and overall functioning, thereby enhancing the quality of life for those affected by ADHD.

The main categories of drugs used in ADHD therapeutics are stimulants and non-stimulants. Stimulants are medications that elevate certain brain chemicals, thereby enhancing attention and focus. Additionally, various psychotherapies such as behavior therapy, cognitive behavioral therapy, interpersonal psychotherapy, and family therapy are utilized. These interventions are tailored for different age groups, including pediatric, adolescent, and adult populations, and are typically dispensed through hospital pharmacies, specialty clinics, retail pharmacies, and e-commerce platforms.

The attention deficit hyperactivity disorder (ADHD) therapeutics market research report is one of a series of new reports that provides attention deficit hyperactivity disorder (ADHD) therapeutics market statistics, including attention deficit hyperactivity disorder (ADHD) therapeutics industry global market size, regional shares, competitors with a attention deficit hyperactivity disorder (ADHD) therapeutics market share, detailed attention deficit hyperactivity disorder (ADHD) therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the attention deficit hyperactivity disorder (ADHD) therapeutics industry. This attention deficit hyperactivity disorder (ADHD) therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The attention deficit hyperactivity disorder (ADHD) therapeutic market consists of revenues earned by entities by providing services such as medication management, behavioral therapy, social skills training, and medication management. The market value includes the value of related goods sold by the service provider or included within the service offering. The attention deficit hyperactivity disorder (ADHD) therapeutic market also includes sales of medication, behavioral modification tools, organization and planning tools, and assistive technologies. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from goods and/or services sold within the specified market and geography through sales, grants, or donations in terms of currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values - that is, they are revenues generated by organizations in the specified geography within the specified market, irrespective of where they are produced. It does not include revenues from resales either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.